JN Baraniuk, M Ali, D Brody, J Maniscalco, E Gaumond, T Fitzgerald, G Wong, A Yuta, JC Mak, PJ Barnes, R Bascom and T Troost
Environmental and Airway Disease Research Facility, University of Maryland, Baltimore, USA.

Glucocorticoids are hypothesized to induce beta2-adrenergic receptors (beta2-R) and their functions. The ability of dexamethasone (DEX) in vitro and beclomethasone dipropionate (BDP) in vivo to induce beta2-R messenger RNA (mRNA) and function was investigated in human nasal mucosa. In this tissue, albuterol does not stimulate exocytosis either in vivo or in vitro (Mullol and coworkers, 1992). Therefore, induction of beta2-R-mediated glandular exocytosis by glucocorticoids was proposed as an unambiguous outcome measure. Human nasal mucosa was cultured for 3 d with and without 1 microM DEX, then challenged with media or 100 microM albuterol. Culture supernatants were collected for measurement of exocytosed glandular products. Explant mRNA was extracted for reverse transcriptase-polymerase chain reaction (RT-PCR), and in situ hybridization of beta2-R mRNA performed. In vivo, normal subjects received saline or BDP for 3 d before albuterol nasal provocation. Concentrations of exocytosed products were measured in nasal secretions. RNA was extracted from nasal epithelial scrapings for RT-PCR. In vitro, DEX treatment induced albuterol-mediated glandular exocytosis (p < 0.04), and increased the steady-state beta2-R/beta- actin mRNA ratio (p < 0.05), and expression of beta2-R mRNA in glands. In vivo, BDP increased the beta2-R/beta-actin mRNA ratio in epithelial scrapings (p < 0.04), but did not induce albuterol-mediated glandular secretion. We conclude that glucocorticoids increase steady-state beta2- R mRNA levels in vivo and in vitro, and can induce beta2-R function as assessed by submucosal gland exocytosis in vitro. While topical BDP induced epithelial beta2-R mRNA, it did not modulate exocytosis from the deeper submucosal glands.

This article has been cited by other articles:

				J. A. Falk, O. A. Minai, and Z. Mosenifar Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 506 - 512. [Abstract] [Full Text] [PDF]

				S. Suissa, R. McGhan, D. Niewoehner, and B. Make Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 535 - 542. [Abstract] [Full Text] [PDF]

				P. J. Barnes Scientific rationale for using a single inhaler for asthma control Eur. Respir. J., March 1, 2007; 29(3): 587 - 595. [Abstract] [Full Text] [PDF]

				D. E. O'Donnell, F. Sciurba, B. Celli, D. A. Mahler, K. A. Webb, C. J. Kalberg, and K. Knobil Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest, September 1, 2006; 130(3): 647 - 656. [Abstract] [Full Text] [PDF]

				K. Fragaki, C. Kileztky, C. Trentesaux, J.-M. Zahm, O. Bajolet, M. Johnson, and E. Puchelle Downregulation by a long-acting beta2-adrenergic receptor agonist and corticosteroid of Staphylococcus aureus-induced airway epithelial inflammatory mediator production Am J Physiol Lung Cell Mol Physiol, July 1, 2006; 291(1): L11 - L18. [Abstract] [Full Text] [PDF]

				M. A. Giembycz and R. Newton Beyond the dogma: novel {beta}2-adrenoceptor signalling in the airways. Eur. Respir. J., June 1, 2006; 27(6): 1286 - 1306. [Abstract] [Full Text] [PDF]

				M. Johnson Corticosteroids: Potential {beta}2-Agonist and Anticholinergic Interactions in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 320 - 325. [Abstract] [Full Text] [PDF]

				M. Johnson Interactions between Corticosteroids and {beta}2-Agonists in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 200 - 206. [Abstract] [Full Text] [PDF]

				N. A. Hanania, P. Darken, D. Horstman, C. Reisner, B. Lee, S. Davis, and T. Shah The Efficacy and Safety of Fluticasone Propionate (250 {micro}g)/Salmeterol (50 {micro}g) Combined in the Diskus Inhaler for the Treatment of COPD Chest, September 1, 2003; 124(3): 834 - 843. [Abstract] [Full Text] [PDF]

				P.J. Barnes Scientific rationale for inhaled combination therapy with long-acting {beta}2-agonists and corticosteroids Eur. Respir. J., January 1, 2002; 19(1): 182 - 191. [Abstract] [Full Text] [PDF]

				J. C. KIPS and R. A. PAUWELS Long-acting Inhaled beta 2-Agonist Therapy in Asthma Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932. [Full Text] [PDF]

				J. E. Fish, E. Israel, J. J. Murray, A. Emmett, R. Boone, S. W. Yancey, and K. A. Rickard Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy Chest, August 1, 2001; 120(2): 423 - 430. [Abstract] [Full Text] [PDF]

				R. M. Sapolsky, L. M. Romero, and A. U. Munck How Do Glucocorticoids Influence Stress Responses? Integrating Permissive, Suppressive, Stimulatory, and Preparative Actions Endocr. Rev., February 1, 2000; 21(1): 55 - 89. [Abstract] [Full Text]

				J. N. BARANIUK, M. ALI, A. YUTA, S.-Y. FANG, and K. NARANCH Hypertonic Saline Nasal Provocation Stimulates Nociceptive Nerves, Substance P Release, and Glandular Mucous Exocytosis in Normal Humans Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 655 - 662. [Abstract] [Full Text]